Source: Annual Congress 2009 - Airway inflammation and host defence
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Weldon, P. McNally, N. G. McElvaney, S. Elborn, R. Levine, C. Taggart (Belfast, United Kingdom; Dublin, Ireland; Bethesda, United States Of America). Decreased levels of secretory leucoprotease inhibitor in the pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. Eur Respir J 2009; 34: Suppl. 53, 924

Member's Comments

No comment yet.

Related content which might interest you: 17β-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor Source: Annual Congress 2010 - Epithelial cells: cell biology and role in lung disease Year: 2010 SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition Source: Eur Respir J 2011; 37: 1083-1090 Year: 2011 Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis Source: Eur Respir J 2015; 46: 384-394 Year: 2015 A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2012; 40: 1475-1482 Year: 2012 Neutrophil elastase and lung damage in cystic fibrosis Source: International Congress 2018 – Proteases: at the cutting edge of lung disease Year: 2018 Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Role of secretory leukocyte protease inhibitor in the development of subclinical emphysema Source: Eur Respir J 2002; 19: 1050-1057 Year: 2002 Inhibition of airway proteases in cystic fibrosis lung disease Source: Eur Respir J 2008; 32: 783-795 Year: 2008 Neutrophilic inflammation predisposes to structural lung disease in cystic fibrosis (CF) via neutrophil elastase activity Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Neutrophil elastase is necessary for increases in active TGF-β in bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 199s Year: 2001 The role of matrix metalloproteinases in cystic fibrosis lung disease Source: Eur Respir J 2011; 38: 721-727 Year: 2011 Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014 α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients Source: Eur Respir J 2007; 29: 240-250 Year: 2007 Decreased levels of elafin in the lungs of patients with acute lung injury as a result of proteolytic cleavage by the proteasome Source: Annual Congress 2012 - Mechanistic studies in airway cell biology Year: 2012 Levels of proteinase 3 and neutrophil elastase in plasma, BAL and biopsies in COPD Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020 A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: Lung Science Conference 2015 Year: 2015 Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002 Intraalveolar levels of tenascin C and thrombin-activatable fibrinolysis inhibitor in interstitial lung diseases Source: Eur Respir J 2003; 22: Suppl. 45, 83s Year: 2003 Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis Source: Eur Respir J, 51 (3) 1701910; 10.1183/13993003.01910-2017 Year: 2018 Targeting of cathepsin S reduces cystic fibrosis-like lung disease Source: Eur Respir J, 53 (3) 1801523; 10.1183/13993003.01523-2018 Year: 2019